Noor Ul Ain Rehman
Tue, May 26, 2026 astatine 7:10 AM CDT 2 min read
In different development, Argus chopped the terms people connected Boston Scientific Corporation (NYSE:BSX) to $95 from $115 connected April 27, reaffirming a Buy standing connected the shares. The standing update came aft the company’s fiscal Q1 net and guidance cut, with the steadfast telling investors successful a probe enactment that the banal has precocious underperformed the broader market. However, it added that the institution remains well-positioned successful high-growth areas specified arsenic cardiovascular, electrophysiology, and neuromodulation, with the absorption mounting much achievable objectives by cutting its outlook. Argus believes that Boston Scientific Corporation’s (NYSE:BSX) terms weakness creates a buying opportunity.
Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets aesculapian devices utilized successful interventional aesculapian procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular conception covers Cardiology and Peripheral Interventions, portion the MedSurg conception comprises Urology, Endoscopy, and Neuromodulation.
While we admit the imaginable of BSX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

3 hours ago
2





English (CA) ·
English (US) ·
Spanish (MX) ·